Trials / Not Yet Recruiting
Not Yet RecruitingNCT07364058
Assessment of Platelet-derived GARP in Atherosclerotic Disease
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Université Catholique de Louvain · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Tissue sample and data collection | Tissue sample and data collection |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2029-01-01
- Completion
- 2029-01-01
- First posted
- 2026-01-23
- Last updated
- 2026-01-27
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT07364058. Inclusion in this directory is not an endorsement.